Desk · CDMO and CRO
CDMO and CRO leadership, before the search starts.
Sites change hands, sponsors roll up platforms and new modalities need new leaders. This desk shows your partners which site, quality and C-suite seats are about to open, and who will make the hire.
Who we cover
CDMOs (small molecule, biologics, cell and gene therapy, sterile fill-finish, packaging), CROs (full-service, specialty, preclinical and safety, central and bioanalytical labs) and device contract manufacturers.
The seats
CEO and president, division or modality president, COO, CFO, chief commercial or business officer, chief quality officer, chief scientific or technical officer, chief medical officer (CRO), general counsel, chief people officer and CIO; SVPs and VPs of operations, site heads and general managers of major sites, VPs of quality, business development, clinical operations, program management and integration, and independent directors.
What opens them
Who usually decides
The sponsor's operating partner, with the board, at a PE-backed company. The board chair at a public company. The COO or SVP operations for a site head.
- A PE firm buys a platform, or a platform adds a company or site.
- A contract organization buys a site from a drug or device maker.
- A new US site, or a capability in a modality new to the company.
- A leader leaves, or a platform creates its first chief quality or commercial officer.
- An FDA warning letter or consent decree at a US site.
- A restructuring, or the loss of a major customer.
See who's about to hire on your desk.
FAQ
What happens to site leadership when a CDMO buys a plant from a drug company?
Site leadership is usually settled around closing. Where the seller's leaders don't transfer, the buyer usually appoints a site head and a quality leader within months.
Other desks:Hospitals and health systems · Post-acute and long-term care · Outpatient and specialty care · Academic medicine · Biotech · Pharma · MedTech and diagnostics